High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease
about
Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblastsRecombinant human sulphamidase: expression, amplification, purification and characterizationClinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quailNew insights into therapeutic options for Pompe diseaseTargeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type IIChinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations.Pompe disease diagnosis and management guideline.Enzyme therapy for Pompe disease: from science to industrial enterprise.Pompe disease: literature review and case seriesSystemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidaseGlycogen storage disease types I and II: treatment updates.Carbohydrate structures of recombinant human alpha-L-iduronidase secreted by Chinese hamster ovary cells.Progress and problems when considering gene therapy for GSD-II.Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.A review of treatment of Pompe disease in infantsA Modified Enzymatic Method for Measurement of Glycogen Content in Glycogen Storage Disease Type IV.Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.Enzymes approved for human therapy: indications, mechanisms and adverse effects.Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I.Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.Translocon pores in the endoplasmic reticulum are permeable to a neutral, polar molecule.Structure of human lysosomal acid α-glucosidase-a guide for the treatment of Pompe disease.Expression of mutant dynamin inhibits toxicity and transport of endocytosed ricin to the Golgi apparatus.Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor.Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.Stabilising normal and mis-sense variant alpha-glucosidase.
P2860
Q24317595-1C1689F9-8E52-44EA-9C24-190D8A400A4BQ24530626-0F35651C-9308-4135-84AB-E486FA084692Q24564823-F0EE5AEE-8BD4-4E5D-A257-1F54E90FBD5DQ26851649-9A4CA60A-1012-414C-B2D8-2D390820C868Q28592264-5305D48F-BE91-4DFD-835C-18A60D85C1BBQ30489156-042AD955-FB09-46D6-B125-D99D7B6BF05CQ34214905-614B2742-0502-4292-B8F1-E56284BEE505Q34567528-C833E509-296C-45F1-B24C-00F6356A7B59Q34954692-58327814-9759-4939-BE49-DDF09F3C5D4BQ35029971-5F6FB4C1-BF68-45E2-B2C5-883AA40C0545Q35586463-7C9CAC96-5FE0-4996-A615-8F55836786B7Q36739605-8F9A1849-E766-4C17-8F72-5E5E6B609722Q36879990-F995B9A7-05F2-4C30-87B4-601763DF9B38Q36960374-25B00CEC-9E02-4BA0-A244-20D9AAB336D2Q37040458-E47BA911-CB11-4491-BD83-1E79B43F4EACQ37259816-CE32DD3B-4CDB-4DC1-9A75-AF48CB053B70Q37290516-703134EA-E816-49E1-9F32-84CA0C897522Q37415869-D969F979-35BA-4CEA-987D-CD99B1F4186CQ38327807-440CF1F9-C545-417B-87A1-DB69076369F5Q38342838-256438CF-4297-42FE-BD9D-747F26119FFDQ38359647-2B01F99B-049D-4711-AEF5-C33528AC9082Q38684097-ABBE2482-B264-4787-8187-E3B36F833F2CQ38982768-2EDC4A1F-EB9B-42E0-AD01-613033959D7AQ40644692-22410523-0964-42D9-B13C-B6F95BD29535Q42502796-740177F8-F7AD-4BAC-ABBF-4A65D37FFD34Q42645986-00A059F9-627F-43B4-8BD4-A87F19052C1FQ42837745-D703739F-DC6D-486B-9BC5-C039C58FBF86Q45133882-2F89C3C8-8739-4CC0-A89D-2D699DC1BFF6Q45877711-9142A833-D99B-4DE8-A103-7F9EA4AF6841Q51805825-E2F1E34C-D7E6-4F2F-8572-F884F91B4C6C
P2860
High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
High-level production of recom ...... om patients with Pompe disease
@ast
High-level production of recom ...... om patients with Pompe disease
@en
type
label
High-level production of recom ...... om patients with Pompe disease
@ast
High-level production of recom ...... om patients with Pompe disease
@en
prefLabel
High-level production of recom ...... om patients with Pompe disease
@ast
High-level production of recom ...... om patients with Pompe disease
@en
P2093
P2860
P356
P1476
High-level production of recom ...... om patients with Pompe disease
@en
P2093
P2860
P356
10.1073/PNAS.93.1.65
P407
P577
1996-01-01T00:00:00Z